FDA Approves Ibrance to Treat Advanced Breast Cancer

Share this content:
FDA Approves Ibrance to Treat Advanced Breast Cancer
FDA Approves Ibrance to Treat Advanced Breast Cancer

(HealthDay News) -- Ibrance (palbociclib) has been approved by the U.S. Food and Drug Administration to treat advanced breast cancer among postmenopausal women.

Ibrance inhibits molecules that spur the growth of cancer cells. The drug is sanctioned for postmenopausal women with estrogen receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer who haven't been given an endocrine-based therapy, the FDA said. It's meant to be given in combination with Femara (letrozole).

Ibrance's effectiveness was evaluated among 165 postmenopausal women with this form of breast cancer. Those treated with Ibrance and letrozole lived about 20.2 months without disease progression, compared with about 10.2 months among women given only letrozole, the FDA said.

The most common side effects of Ibrance included neutropenia, fatigue, anemia, upper respiratory infection, nausea, hair loss, diarrhea, thrombocytopenia, loss of appetite, nerve damage, and epistaxis. Doctors should tell potential users of these risks, the FDA advised.

Ibrance is marketed by Pfizer, based in New York City.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Some California Mosquitoes Can Carry Zika Virus

Some California Mosquitoes Can Carry Zika Virus

Aedes aegypti mosquitoes found to transmit Zika virus

Periodontal Inflammation a Risk With Tongue Piercing

Periodontal Inflammation a Risk With Tongue Piercing

And, two young females with tongue piercings have deep lingual infrabony lesions, periodontitis

Risk of OD Highest for First Days of Opioid  Benzodiazepine Use

Risk of OD Highest for First Days of ...

Five-fold increased risk of opioid-related overdose during first 90 days of concurrent use

is free, fast, and customized just for you!




Already a member?

Sign In Now »